Name | Number of supported studies | Average coverage | |
---|---|---|---|
microglial cell | 7 studies | 29% ± 9% | |
endothelial cell | 6 studies | 22% ± 6% | |
dendritic cell | 6 studies | 24% ± 9% | |
macrophage | 6 studies | 25% ± 7% | |
epithelial cell | 5 studies | 24% ± 9% | |
GABAergic neuron | 5 studies | 40% ± 18% | |
monocyte | 5 studies | 25% ± 6% | |
non-classical monocyte | 4 studies | 22% ± 9% | |
astrocyte | 4 studies | 27% ± 9% | |
oligodendrocyte precursor cell | 4 studies | 31% ± 7% | |
oligodendrocyte | 4 studies | 23% ± 5% | |
classical monocyte | 3 studies | 29% ± 2% | |
myeloid cell | 3 studies | 19% ± 3% | |
ciliated cell | 3 studies | 24% ± 7% | |
glutamatergic neuron | 3 studies | 60% ± 5% | |
B cell | 3 studies | 21% ± 3% | |
goblet cell | 3 studies | 33% ± 21% | |
interneuron | 3 studies | 40% ± 18% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 44% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 2229.62 | 459 / 459 | 100% | 40.31 | 1116 / 1118 |
lung | 100% | 1915.05 | 577 / 578 | 100% | 15.61 | 1153 / 1155 |
brain | 100% | 1096.17 | 2632 / 2642 | 100% | 10.57 | 703 / 705 |
intestine | 100% | 1803.38 | 966 / 966 | 99% | 13.71 | 521 / 527 |
esophagus | 100% | 1642.25 | 1444 / 1445 | 99% | 17.12 | 181 / 183 |
bladder | 100% | 1706.19 | 21 / 21 | 99% | 13.11 | 497 / 504 |
prostate | 100% | 1685.06 | 245 / 245 | 99% | 18.21 | 495 / 502 |
stomach | 100% | 1274.76 | 359 / 359 | 99% | 13.91 | 282 / 286 |
ovary | 100% | 1983.98 | 180 / 180 | 98% | 8.72 | 422 / 430 |
uterus | 100% | 1830.08 | 170 / 170 | 98% | 12.60 | 450 / 459 |
thymus | 100% | 1381.67 | 653 / 653 | 97% | 12.12 | 588 / 605 |
pancreas | 98% | 747.05 | 322 / 328 | 99% | 15.06 | 176 / 178 |
kidney | 100% | 1250.76 | 89 / 89 | 97% | 15.37 | 870 / 901 |
liver | 100% | 852.76 | 226 / 226 | 93% | 8.35 | 377 / 406 |
adrenal gland | 100% | 895.29 | 258 / 258 | 89% | 8.82 | 205 / 230 |
skin | 100% | 1745.81 | 1807 / 1809 | 85% | 8.10 | 401 / 472 |
blood vessel | 100% | 3252.14 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 12.03 | 29 / 29 |
spleen | 100% | 1743.23 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 13.35 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 5.07 | 1 / 1 |
adipose | 100% | 1839.28 | 1203 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 2421.28 | 913 / 929 | 0% | 0 | 0 / 0 |
muscle | 98% | 727.20 | 787 / 803 | 0% | 0 | 0 / 0 |
heart | 96% | 799.45 | 824 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 38% | 1.90 | 30 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0031397 | Biological process | negative regulation of protein ubiquitination |
GO_0030162 | Biological process | regulation of proteolysis |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0031463 | Cellular component | Cul3-RING ubiquitin ligase complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0042802 | Molecular function | identical protein binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005515 | Molecular function | protein binding |
Gene name | SPOPL |
Protein name | Speckle type BTB/POZ protein like Speckle-type POZ protein-like (HIB homolog 2) (Roadkill homolog 2) |
Synonyms | |
Description | FUNCTION: Component of a cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, but with relatively low efficiency. Cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complexes containing homodimeric SPOPL or the heterodimer formed by SPOP and SPOPL are less efficient than ubiquitin ligase complexes containing only SPOP. May function to down-regulate the activity of cullin-RING-based BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complexes that contain SPOP. . |
Accessions | ENST00000430968.5 F8WD02 ENST00000280098.9 ENST00000420679.1 Q6IQ16 F8WBB7 |